| 貨號 | 規(guī)格 | 價格 | 上海 | 北京 | 武漢 | 南京 | 購買數(shù)量 |
|---|---|---|---|---|---|---|---|
S81999-2mg |
99.2% | ￥800.00 | 2 | - | - | - |
|
S81999-5mg |
99.2% | ￥1400.00 | 6 | - | - | - |
|
S81999-10mg |
99.2% | ￥2380.00 | 6 | - | - | - |
|
S81999-25mg |
99.2% | ￥4100.00 | 5 | - | - | - |
|
S81999-50mg |
≥98% | ￥5900.00 | 貨期：2-3天 | - | - | - |
|
S81999-100mg |
≥98% | ￥8100.00 | 貨期：2-3天 | - | - | - |
|
Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist, used for treatment of chronic liver disease.
| 產(chǎn)品描述： | Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist, used for treatment of chronic liver disease. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶點： | Thrombopoietin Receptor;Thrombin;?ThrombopoietinReceptor | ||||||||||||||||||||
| 體外研究： | Lusutrombopag acts selectively on the human TPO receptor and activates signal transduction pathways that promote the proliferation and differentiation of bone marrow cells into megakaryocytes, thereby increasing platelet levels | ||||||||||||||||||||
| 參考文獻： | 1. Kim ES, et al. Lusutrombopag: First Global Approval. Drugs. 2016 Jan;76(1):155-8. | ||||||||||||||||||||
| 溶解性： | soluble in DMSO | ||||||||||||||||||||
| 保存條件： | -20℃ | ||||||||||||||||||||
| 配置溶液濃度參考： |
|
||||||||||||||||||||
| 注意： | 部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
滬公網(wǎng)安備 31011702002021號
危險品化學(xué)品經(jīng)營許可證（不帶存儲）
營業(yè)執(zhí)照(三證合一)
北京